Ueki Kenji, Tsuchimoto Akihiro, Matsukuma Yuta, Ataka Eri, Okamoto Hirofumi, Tanaka Shigeru, Masutani Kosuke, Kitazono Takanari, Nakano Toshiaki
Department of Medicine and Clinical Science, Kyushu University, Fukuoka, Japan.
Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Clin Kidney J. 2024 Apr 17;17(6):sfae104. doi: 10.1093/ckj/sfae104. eCollection 2024 Jun.
Phospholipase A2 receptor (PLA2R) is a major target antigen in idiopathic membranous nephropathy (MN). Anti-PLA2R antibodies are mainly of the immunoglobulin G (IgG) subclass IgG4, although other IgG subclass depositions in glomeruli may also be detected. However, the importance of the subclass of the IgG deposit has not been proven. Thus we investigated clinical findings from patients with idiopathic MN in relation to glomerular PLA2R deposition and IgG subclass.
We enrolled 132 Japanese patients with biopsy-proven idiopathic MN in a multicentre retrospective observational study. We investigated the complete remission rate as the primary outcome and the development of end-stage kidney disease (ESKD) as the secondary outcome in relation to glomerular PLA2R deposition. Moreover, we evaluated prognostic factors, including glomerular IgG subclass, in the PLA2R-positive group.
The percentage of cases with glomerular PLA2R deposition was 76.5% ( = 101). The first complete remission rate of the PLA2R-positive group was worse than that of the PLA2R-negative group (logrank test < .001). ESKD incidence did not significantly differ between the glomerular PLA2R-negative and PLA2R-positive MN groups (logrank test = .608). In the PLA2R-positive group, higher PLA2R intensities and IgG2 staining were associated with a poorer first complete remission rate (logrank test < .001 and = .032, respectively). Cox proportional hazards analysis also showed that strong PLA2R deposition and positive IgG2 staining were significantly associated with a failure to reach complete remission [hazard ratio 2.09 ( = .004) and 1.78 ( = .030), respectively].
Our results suggest that intense glomerular PLA2R and IgG2 positivity predict a poor proteinuria remission rate in idiopathic MN.
磷脂酶A2受体(PLA2R)是特发性膜性肾病(MN)的主要靶抗原。抗PLA2R抗体主要为免疫球蛋白G(IgG)亚类IgG4,不过也可能检测到肾小球中其他IgG亚类的沉积。然而,IgG沉积物亚类的重要性尚未得到证实。因此,我们调查了特发性MN患者的临床发现与肾小球PLA2R沉积及IgG亚类的关系。
我们纳入了132例经活检证实为特发性MN的日本患者,进行一项多中心回顾性观察研究。我们将完全缓解率作为主要结局,将终末期肾病(ESKD)的发生作为次要结局,研究其与肾小球PLA2R沉积的关系。此外,我们在PLA2R阳性组中评估了包括肾小球IgG亚类在内的预后因素。
肾小球PLA2R沉积的病例百分比为76.5%(n = 101)。PLA2R阳性组的首次完全缓解率低于PLA2R阴性组(对数秩检验P <.001)。肾小球PLA2R阴性和阳性的MN组之间ESKD发生率无显著差异(对数秩检验P = 0.608)。在PLA2R阳性组中,较高的PLA2R强度和IgG2染色与较差的首次完全缓解率相关(对数秩检验分别为P <.001和P = 0.032)。Cox比例风险分析还显示,强烈的PLA2R沉积和阳性的IgG2染色与未能达到完全缓解显著相关[风险比分别为2.09(P = 0.004)和1.78(P = 0.030)]。
我们的结果表明,强烈的肾小球PLA2R和IgG2阳性预示着特发性MN患者蛋白尿缓解率不佳。